Edwards Lifesciences PASCAL System Meets Primary Endpoint in CLASP II TR Study
Edwards Lifesciences (EW) announced that its PASCAL system successfully met the primary endpoint in the CLASP II tricuspid regurgitation (TR) clinical trial. The study demonstrated that the PASCAL system achieved a significant reduction in tricuspid regurgitation compared to patients receiving standard medical therapy. The results from the CLASP II TR study provide critical clinical validation for the PASCAL transcatheter edge-to-edge repair system. This development positions Edwards Lifesciences to potentially expand its footprint in the tricuspid valve market, offering a minimally invasive alternative for patients suffering from significant tricuspid regurgitation.
Tickers: $EW
Topics: clinical trial results medical device performance tricuspid regurgitation